Author Topic: (Abst.) Long-term outcomes after AHSCT for MS [5-year study of 281 PwMS]  (Read 83 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
An article by some of the same authors, in Nature abstracted in PubMed, June 18, 2017:

Nat Rev Neurol. 2017 Jun 16.

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Muraro PA1, Martin R2, Mancardi GL3,4, Nicholas R1, Sormani MP5, Saccardi R6.

Author information
Division of Brain Sciences, Imperial College London, Burlington Danes Building, 190 Du Cane Road, London W12 0NN, UK.
Neuroimmunology and Multiple Sclerosis Research, Neurology Clinic, University Hospital Zurich, University Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Largo Paolo Daneo 3, 16145 Genova, Italy.
Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy.
Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, 16132, Genova, Italy.
Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Largo Brambilla, 3-50134 Firenze, Italy.

Autologous haematopoietic stem cell transplantation (AHSCT) is a multistep procedure that enables destruction of the immune system and its reconstitution from haematopoietic stem cells. Originally developed for the treatment of haematological malignancies, the procedure has been adapted for the treatment of severe immune-mediated disorders.

Results from ∼20 years of research make a compelling case for selective use of AHSCT in patients with highly active multiple sclerosis (MS), and for controlled trials. Immunological studies support the notion that AHSCT causes qualitative immune resetting, and have provided insight into the mechanisms that might underlie the powerful treatment effects that last well beyond recovery of immune cell numbers.

Indeed, studies have demonstrated that AHSCT can entirely suppress MS disease activity for 4-5 years in 70-80% of patients, a rate that is higher than those achieved with any other therapies for MS. Treatment-related mortality, which was 3.6% in studies before 2005, has decreased to 0.3% in studies since 2005.

Current evidence indicates that the patients who are most likely to benefit from and tolerate AHSCT are young, ambulatory and have inflammatory MS activity. Clinical trials are required to rigorously test the efficacy, safety and cost-effectiveness of AHSCT against highly active MS drugs.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post February 20, 2017, 10:12:37 am
by agate
0 Replies
Last post April 16, 2017, 02:48:49 pm
by agate
0 Replies
Last post May 16, 2017, 12:06:36 pm
by agate
0 Replies
Last post March 01, 2018, 11:30:58 am
by agate
0 Replies
Last post April 19, 2020, 08:53:27 pm
by agate